Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera ...

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.